The role of nutraceutical supplements in the treatment of dyslipidemia

Journal of Clinical Hypertension

Volumn 14, Issue 2, 2012, Pages 121-132

  Houston, Mark ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT THOMAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLICIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTIN; CURCUMIN; GAMMA TOCOTRIENOL; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HISTIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAEMPFEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYCOPENE; MONOCYTE CHEMOTACTIC PROTEIN 1; MORIN; MYRICETIN; NICOTINIC ACID; NUTRACEUTICAL; OLEIC ACID; PANTETHINE; PHYTOSTEROL; POLICOSANOL; POLYPHENOL; POMEGRANATE EXTRACT; RUTOSIDE; TRIACYLGLYCEROL; UBIDECARENONE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; EXERCISE; FLUSHING; GASTRITIS; GENE EXPRESSION; GOUT; HEART PALPITATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERPIGMENTATION; HYPERURICEMIA; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; TACHYCARDIA; ULCER; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

ATHEROSCLEROSIS; DIETARY FATS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, VLDL; OXIDATIVE STRESS; PANTETHEINE; STILBENES; TOCOTRIENOLS; TRIGLYCERIDES; VASCULAR DISEASES; VASODILATOR AGENTS;

EID: 84856237816     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00576.x     Document Type: Review

References (111)

1. Kannel WB, Castelli WD, Gordon T, et al. Serum cholesterol, lipoproteins and risk of coronary artery disease. The Framingham Study. Ann Intern Med. 1971;74:1-12.
2. Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev Cardiovasc Ther. 2010;8:821-833.
3. Tian N, Penman AD, Mawson AR, et al. Association between circulating specific leukocyte types and blood pressure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens. 2010;4:272-283.
4. Ungvari Z, Kaley G, de Cabo R, et al. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65:1028-1041.
5. Houston MC, Fazio S, Chilton FH, et al. Non pharmacologic treatment of dyslipidemia. Prog Cardiovasc Dis. 2009;52:61-94.
6. Plourde M, Vohl MC, Vandal M, et al. Plasma n-3 fatty acid supplement is modulated by apoE epsilon 4 but not by the common PPAR-alpha L162 polymorphism in men. Br J Nutr. 2009;102:1121-1124.
7. Neiminen T, Kahonen M, Viiri LE, et al. Pharmacogenetics of apoliproprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics. 2008;9:1475-1486.
8. Shih DM, Lusis AJ. Theroles of PON 1 and PON 2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20:288-292.
9. Calkin AC, Tontonoz P. Genome-wide association studies identify new targets in cardiovascular disease. Sci Transl Med. 2010;2:48.
10. Djousse L, Caziano JM. Dietary cholesterol and coronary artery disease: a systematic review. Curr Atheroscler Rep. 2009;11:418-422.
11. Werko L. End of the road for the diet-heart theory? Scand Cardiovasc J. 2008;42:250-255.
12. Erkkila A, de Mello VD, Riserus U, Laaksonen DE. Dietary fatty acids and cardiovascular disease: an epidemiological approach. Prog Lipid Res. 2008;47:172-187.
13. Weinberg SL. The diet-heart hypothesis: a critique. J Am Coll Cardiol. 2004;43:731-733.
14. Mozaffarian D, Willet WC. Trans fatty acids and cardiovascular risk: a unique cardiometabolic imprint. Curr Atheroscler Rep. 2007;9:486-493.
15. Chen CL, Tetri LH, Neuschwander-Tetri BA, et al. A mechanism by which dietary trans fats cause atherosclerosis. J Nutr Biochem. 2011;22:649-655.
16. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate and cardiovascular disease. Am J Clin Nutr. 2010;91:502-509.
17. Otvos JD, Mora S, Shalaurova I, et al. Clinical Implications of discordance between low density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105-113.
18. Hodge AM, Jenkins AJ, English DR, et al. NMR determined lipoprotein subclass profile is associated with dietary composition and body size. Nutr Metab Cardiovasc Dis. 2011;21:603-609.
19. Asztalos BF, Tani M, Schaefer E. Metabolic and functional of HDL subspecies. Curr Opin Lipidol. 2011;22:176-185.
20. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
21. Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results form the MONICA/KORA Augsburg study. J Intern Med. 2011;271:43-50.
22. Lamarche B, Tchernof A, Mooriani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
23. Kruth HS. Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low density lipoprotein particles. Curr Opin Lipidol. 2011;22:386-393.
24. Zhao ZW, Zhu XL, Luo YK, et al. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with angiographic coronary lesion complexity in patients with coronary artery disease. Clin Cardiol. 2011;34:172-177.
25. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
27. Harper CR, Jacobson TA. Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc. 2010;85:440-445.
28. Curtiss LK. Reversing atherosclerosis? N Engl J Med. 2009;360:1144-1146.
29. Shen GX. Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. Mol Cell Biochem. 2003;246:69-74.
30. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
31. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21:324-328.
32. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170, 255 patients from 76 randomized trials. QJM. 2011;104:109-124.
33. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22:544-550.
34. Russo MW, Scobev M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412-422.
35. Moosmann B, Behl C. Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med. 2004;14:273-281.
36. Liu CS, Lii CK, Chang LL, et al. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients. Nutr Res. 2010;30:118-124.
37. Wyman M, Leonard M, Morledge T. Coenzyme Q 10: a therapy for hypertension and statin-induced myalgia? Clev Clin J Med. 2010;77:435-442.
38. Mortensen SA. Low coenzyme Q levels and the outcome of statin treatment in heart failure. J Am Coll Cardiol. 2011;57:1569.
39. Shojaei M, Djalali M, Khatami M, et al. Effects of carnitine and coenzyme Q 10 on lipid profile and serum levels of lipoprotein (a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis. 2011;5:114-118.
40. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215:23-29.
41. Avis HJ, Hargreaves IP, Ruiter JP, et al. Rosuvastatin lowers coenzyme Q 10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia. J Pediatr. 2011;158:458-462.
42. Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyloysis and an important clinical link with hypothyroidism. Int J Cardiol. 2007;119:374-376.
43. Nijjar PS, Burke FM, Bioesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4:248-258.
44. Houston MC. Juice powder concentrate and systemic blood pressure, progression of coronary artery calcium and antioxidant status in hypertensive subjects: a pilot study evidence based complementary. Alternat Med. 2007;4:455-462.
45. Budoff MJ, Ahmadi N, Gul KM, et al. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med. 2009;49:101-107.
46. Ruparelia N, Digby JE, Choudhury RP. Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol. 2010.
47. Al-Mohissen MA, Pun SC, Frohlich JJ. Niacin: from mechanisms of action to therapeutic uses. Mini Rev Med Chem. 2010;10:204-217.
48. The Coronary Drug Project Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
49. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24months of combination statin and extended release niacin on carotid intima-media thickness: ARBITER 3.
50. Lee JM, Robson MD, Yu LM, et al. Effects of high dose modified release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794.
51. Taylor AJ, Villines TC, Stanek EJ, et al. Extended release niacin or ezetimibe and carotid intima media thickness. N Engl J Med. 2009;361:2113-2122.
52. AIM HIGH Investigators. The role of niacin in raising high density lipoprotein cholesterols to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538-543.
53. Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295:2262-2269.
54. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr. 2006;95:968-975.
55. Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
56. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-1693.
57. Patch CS, Tapsell LC, Williams PG, Gordon M. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Vasc Health Risk Manag. 2006;2:157-162.
58. Demonty I, Ras RT, van der Knaap HC, et al. Continuous dose response relationship of the LDL cholesterol lowering effect of phytosterol intake. J Nutr. 2009;139:271-284.
59. Othman RA, Moghadasian MH. Beyond cholesterol lowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties. Nutr Rev. 2011;69:371-382.
60. Sabeva NS, McPhaul CM, Li X, et al. Phytosterols differently influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. J Nutr Biochem. 2011;22:777-783.
61. Sacks FM, Lichtenstein A, Van Horn L, et al. American Heart Association Nutrition Committee. Circulation. 2006;113:1034-1044.
62. Harland JI, Haffner TA. Systemic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25g soya protein per day and blood cholesterol. Atherosclerosis. 2008;200:13-27.
63. Singh DK, Banerjee S, Porter TD. Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells. J Nutr Biochem. 2009;20:816-822.
64. Tinahones FJ, Rubio MA, Garrido-Sanchez L, et al. Green tea reduces LDL oxidability and improves vascular function. J Am Coll Nutr. 2008;27:209-213.
65. Brown AL, Lane J, Holyoak C, et al. Health effects of green tea catechins in overweight and obese men: a randomized controlled cross-over trial. Br J Nut. 2011;7:1-10.
66. Zheng XX, Xu YL, Li SH, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94:601-610.
67. Saremi A, Arora R. The utility of omega-3 fatty acids in cardiovascular disease. Am J Ther. 2009;16:421-436.
68. Rissanen T, Voutilainen S, Nyyssonen K, et al. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 2000;102:2677-2679.
69. Davis W, Rockway S, Kwasny M. Effect of a combined therapeutic approach of intensive lipid management, omega 3 fatty acid supplementation, and increased serum 25(OH) D on coronary calcium scores in asymptomatic adults. Am J Ther. 2009;16:326-332.
70. Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA lipid intervention study (JELIS) investigators. Lancet. 2007;369:1090-1098.
71. Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther. 2009;16:183-192.
72. Kelley DS, Siegal D, Vemuri M, et al. Docosahexaenoic acid supplementation decreases remnant-like particle cholesterol and increases the (n-3) index in hypertriglyceridemic men. J Nutr. 2008;138:30-35.
73. Maki KC, Dicklin MR, Davidson MH, et al. COMBination of prescription omega-3 with simvastatin (COMBOS) investigators. Am J Cardiol. 2010;105:1409-1412.
74. Micallef MA, Garg ML. The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women. J Nutr. 2008;138:1085-1090.
75. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085-1094.
76. Prasad K. Flaxseed and cardiovascular health. J Cardiovasc Pharmacol. 2009;54:369-377.
77. Bioedon LT, Balkai S, Chittams J, et al. Flaxseed and cardiovascular risk factors: results from a double-blind, randomized controlled clinical trial. J Am Coll Nutr. 2008;27:65-74.
78. Mandasescu S, Mocanu V, Dascalita AM, et al. Flaxseed supplementation in hyperlipidemic patients. Rev Med Chir Soc Med Nat lasi. 2005;109:502-506.
79. Bester D, Esterhuyse AJ, Truter EJ, van Rooven J. Cardiovascular effects of edible oils: a comparison between four popular edible oils. Nutr Res Rev. 2010;23:334-348.
80. Brown JM, Shelness GS, Rudel LL. Monounsaturated fatty acids and atherosclerosis: opposing views from epidemiology and experimental animal models. Curr Atheroscler Rep. 2007;9:494-500.
81. Bogani P, Gali C, Villa M, Visioli F. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis. 2007;190:181-186.
82. Covas MI. Olive oil and the cardiovascular system. Pharmacol Res. 2007;55:175-186.
83. Wu WH, Kang YP, Wang NH, et al. Sesame ingestion affects sex hormones, antioxidant status and blood lipids in postmenopausal women. J Nutr. 2006;136:1270-1275.
84. Namiki M. Nutraceutical functions of sesame: a review. Crit Rev Food Sci Nutr. 2007;47:651-673.
85. Qureshi AA, Sami SA, Salser WA, Khan FA. Synergistic effect of tocotrienol-rich fraction (TRF 25) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans. J Nutr Biochem. 2001;12:318-329.
86. Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3 methylglutaryl coenzyme a reductase stimulated by delta-and gamma-tocotrienols. J Biol Chem. 2006;281:54-61.
87. Prasad K. Tocotrienols and cardiovascular health. Curr Pharm Des. 2011;17:2147-2154.
88. McRae MP. Treatment of hyperlipoproteinemia with pantethine a review and analysis of efficacy and tolerability. Nutr Res. 2005;25:319-333.
89. Kelly G. Pantethine: a review of its biochemistry and therapeutic applications. Altern Med Rev. 1997;2:365-377.
90. Horvath Z, Vecsei L. Current medical aspects of pantethine. Ideggyogy Sz. 2009;8:220-229.
91. Pins LL, Keenan JM. Dietary and nutraceutical options for managing the hypertriglyceridemic patient. Prog Cardiovasc Nurs. 2006;21:89-93.
92. No Authors listed. Pantethine monograph. Altern Med Rev. 2010;15:279-282.
93. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765-772.
94. Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the natural standard research collaboration. Complement Ther Med. 2005;13:279-290.
95. Nohr LA, Rasmussen LB, Straand J. Resin from the Mukul Myrrh tree, guggul, can it be used for treating hypercholesterolemia: a randomized, controlled study. Complement Ther Med. 2009;17:16-22.
96. Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentration in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167:346-353.
97. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992;36:273-275.
98. Aviram M. Atherosclerosis: cell biology and lipoproteins - oxidative stress and paraoxonases regulate atherogenesis. Curr Opin Lipidol. 2010;21:163-164.
99. Fuhrman B, Volkova N, Aviram M. Pomegranate juice polyphenols increase recombinant paroxonase-1 binding to high density lipoprotein: studies in vitro and in diabetic patients. Nutrition. 2010;26:359-366.
100. Avairam M, Rosenblat M, Gaitine D, et al. Pomegranate juice consumption for 3years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23:423-433.
101. Mattiello T, Trifiro E, Jotti GS, Pulcinelli FM. Effects of pomegranate juice and extract polypyenols on platelet function. J Med Food. 2009;12:334-339.
102. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 2000;71:1062-1076.
103. Davidson MH, Maki KC, Dicklin MR, et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol. 2009;104:936-942.
104. Cesar TB, Aptekman NP, Araujo MP, et al. Orange juice decreases low density lipoprotein cholesterol in hypercholesterolemic subjects and improves lipid transfer to high density lipoprotein in normal and hypercholesterolemic subjects. Nutr Res. 2010;30:689-694.
105. Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3 hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009;72:1352-1354.
106. Mollace V, Sacco I, Janda E, et al. Hypolipidemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitotherapia. 2011;82:309-316.
107. McRae MP. Vitamin C supplementation lowers serum low-density cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. J Chiropr Med. 2008;7:48-58.
108. McRae MP. The efficacy of vitamin C supplementation on reducing total serum cholesterol in human subjects: a review of 51 experimental trials. J Chiropr Med. 2006;5:2-12.
109. Palozza P, Simone R, Gatalano A, et al. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem. 2011;22:971-978.
110. Houston M, Sparks W. Effect of combination pantethine, plant sterols, green tea extract, delta-tocotrienol and phytolens on lipid profiles in patients with hyperlipidemia. JANA. 2010;13:15-20.
111. Studer M, Briel M, Leimenstoll B, et al. Effect of different anti-lipidemic agents and diets on mortality: a systemic review. Arch Int Med. 2005;165:725-730.